CONTEXT: Soybean oil-based lipid emulsions are the only Food and Drug Administration-approved lipid formulation for clinical use in parenteral nutrition (PN). Recently concerns with its use have been raised due to the proinflammatory effects that may lead to increased complications because they are rich in ω-6 polyunsaturated fatty acids. METHODS: This was a prospective, randomized, controlled, crossover study comparing the vascular, metabolic, immune, and inflammatory effects of 24-h infusion of PN containing soybean oil-based lipid emulsion (Intralipid), olive oil-based (ClinOleic), lipid free, and normal saline in 12 healthy subjects. RESULTS:Soybean oil-PN increased systolic blood pressure compared with olive oil-PN (P < 0.05). Soybean oil PN reduced brachial artery flow-mediated dilatation from baseline (-23% at 4 h and -25% at 24 h, both P < 0.01); in contrast, olive oil PN, lipid free PN, and saline did not change either systolic blood pressure or flow-mediated dilatation. Compared with saline, soybean oil PN, olive oil PN, and lipid free PN similarly increased glucose and insulin concentrations during infusion (P < 0.05). There were no significant changes in plasma free fatty acids, lipid profile, inflammatory and oxidative stress markers, immune function parameters, or sympathetic activity between soybean oil- and olive oil-based lipid emulsions. CONCLUSION: The 24-h infusion of PN containing soybean oil-based lipid emulsion increased blood pressure and impaired endothelial function compared with PN containing olive oil-based lipid emulsion and lipid-free PN in healthy subjects. These vascular changes may have significant implications in worsening outcome in subjects receiving nutrition support. Randomized controlled trials with relevant clinical outcome measures are needed in patients receiving PN with olive oil-based and soybean oil-based lipid emulsions.
RCT Entities:
CONTEXT: Soybeanoil-based lipid emulsions are the only Food and Drug Administration-approved lipid formulation for clinical use in parenteral nutrition (PN). Recently concerns with its use have been raised due to the proinflammatory effects that may lead to increased complications because they are rich in ω-6 polyunsaturated fatty acids. METHODS: This was a prospective, randomized, controlled, crossover study comparing the vascular, metabolic, immune, and inflammatory effects of 24-h infusion of PN containing soybeanoil-based lipid emulsion (Intralipid), oliveoil-based (ClinOleic), lipid free, and normal saline in 12 healthy subjects. RESULTS:Soybeanoil-PN increased systolic blood pressure compared with oliveoil-PN (P < 0.05). Soybeanoil PN reduced brachial artery flow-mediated dilatation from baseline (-23% at 4 h and -25% at 24 h, both P < 0.01); in contrast, oliveoil PN, lipid free PN, and saline did not change either systolic blood pressure or flow-mediated dilatation. Compared with saline, soybeanoil PN, oliveoil PN, and lipid free PN similarly increased glucose and insulin concentrations during infusion (P < 0.05). There were no significant changes in plasma free fatty acids, lipid profile, inflammatory and oxidative stress markers, immune function parameters, or sympathetic activity between soybeanoil- and oliveoil-based lipid emulsions. CONCLUSION: The 24-h infusion of PN containing soybeanoil-based lipid emulsion increased blood pressure and impaired endothelial function compared with PN containing oliveoil-based lipid emulsion and lipid-free PN in healthy subjects. These vascular changes may have significant implications in worsening outcome in subjects receiving nutrition support. Randomized controlled trials with relevant clinical outcome measures are needed in patients receiving PN with oliveoil-based and soybeanoil-based lipid emulsions.
Authors: Stephen Clement; Susan S Braithwaite; Michelle F Magee; Andrew Ahmann; Elizabeth P Smith; Rebecca G Schafer; Irl B Hirsch; Irl B Hirsh Journal: Diabetes Care Date: 2004-02 Impact factor: 19.112
Authors: M Roden; T B Price; G Perseghin; K F Petersen; D L Rothman; G W Cline; G I Shulman Journal: J Clin Invest Date: 1996-06-15 Impact factor: 14.808
Authors: R J Widmer; M A Freund; A J Flammer; J Sexton; R Lennon; A Romani; N Mulinacci; F F Vinceri; L O Lerman; A Lerman Journal: Eur J Nutr Date: 2012-08-08 Impact factor: 5.614
Authors: Guillermo E Umpierrez; Ronnie Spiegelman; Vivian Zhao; Dawn D Smiley; Ingrid Pinzon; Daniel P Griffith; Limin Peng; Timothy Morris; Menghua Luo; Hermes Garcia; Christopher Thomas; Christopher A Newton; Thomas R Ziegler Journal: Crit Care Med Date: 2012-06 Impact factor: 7.598
Authors: María Auxiliadora Baena-Gómez; María José De La Torre Aguilar; María Dolores Mesa; Juan Luis Pérez Navero; Mercedes Gil-Campos Journal: Nutrients Date: 2015-08-28 Impact factor: 5.717